Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Research analysts at Leerink Swann upped their FY2017 earnings estimates for Sarepta Therapeutics in a note issued to investors on Wednesday. Leerink Swann analyst J. Schwartz now forecasts that the biotechnology company will post earnings of ($3.12) per share for the year, up from their prior estimate of ($3.71). Leerink Swann currently has a “Outperform” rating and a $66.00 price objective on the stock. Leerink Swann also issued estimates for Sarepta Therapeutics’ Q4 2017 earnings at ($0.40) EPS, FY2018 earnings at ($0.47) EPS and FY2019 earnings at $1.17 EPS.
Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.66. The firm had revenue of $45.95 million for the quarter, compared to the consensus estimate of $41.29 million. Sarepta Therapeutics had a negative net margin of 112.08% and a negative return on equity of 62.44%. During the same period in the prior year, the company posted ($0.95) earnings per share. TRADEMARK VIOLATION WARNING: “Sarepta Therapeutics, Inc. to Post FY2017 Earnings of ($3.12) Per Share, Leerink Swann Forecasts (SRPT)” was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://www.com-unik.info/2017/11/01/sarepta-therapeutics-inc-to-post-fy2017-earnings-of-3-12-per-share-leerink-swann-forecasts-srpt.html.
SRPT has been the topic of a number of other research reports. Credit Suisse Group restated an “outperform” rating and issued a $81.00 target price on shares of Sarepta Therapeutics in a research note on Monday, October 2nd. Robert W. Baird restated a “buy” rating and issued a $101.00 target price on shares of Sarepta Therapeutics in a research note on Tuesday, October 17th. William Blair restated an “outperform” rating on shares of Sarepta Therapeutics in a research note on Monday, October 2nd. Zacks Investment Research upgraded Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, August 2nd. Finally, Piper Jaffray Companies restated an “overweight” rating and issued a $55.00 target price (up previously from $50.00) on shares of Sarepta Therapeutics in a research note on Thursday, September 7th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and sixteen have issued a buy rating to the company. Sarepta Therapeutics has a consensus rating of “Buy” and an average target price of $63.59.
Shares of Sarepta Therapeutics (NASDAQ SRPT) opened at 49.31 on Monday. Sarepta Therapeutics has a 52 week low of $26.26 and a 52 week high of $52.67. The firm’s market capitalization is $3.17 billion. The firm’s 50-day moving average is $48.43 and its 200-day moving average is $38.92.
In related news, SVP Shamim Ruff sold 11,500 shares of the stock in a transaction that occurred on Tuesday, October 3rd. The stock was sold at an average price of $50.00, for a total value of $575,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 9.60% of the stock is currently owned by company insiders.
Large investors have recently bought and sold shares of the stock. Prentiss Smith & Co. Inc. increased its holdings in shares of Sarepta Therapeutics by 772.2% in the second quarter. Prentiss Smith & Co. Inc. now owns 3,576 shares of the biotechnology company’s stock valued at $121,000 after purchasing an additional 3,166 shares during the last quarter. Fox Run Management L.L.C. acquired a new stake in shares of Sarepta Therapeutics in the third quarter valued at approximately $204,000. Ameritas Investment Partners Inc. increased its holdings in shares of Sarepta Therapeutics by 6.3% in the second quarter. Ameritas Investment Partners Inc. now owns 4,561 shares of the biotechnology company’s stock valued at $154,000 after purchasing an additional 271 shares during the last quarter. Cubist Systematic Strategies LLC increased its holdings in shares of Sarepta Therapeutics by 116.4% in the second quarter. Cubist Systematic Strategies LLC now owns 4,600 shares of the biotechnology company’s stock valued at $155,000 after purchasing an additional 2,474 shares during the last quarter. Finally, Strs Ohio acquired a new stake in shares of Sarepta Therapeutics in the third quarter valued at approximately $208,000. 65.46% of the stock is owned by hedge funds and other institutional investors.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
What are top analysts saying about Sarepta Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sarepta Therapeutics Inc. and related companies.